Joel Parker
Psychiatry · Phoenix, AZNPI 1336134352
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 648 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 27.1% of the total. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sunovion Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$980
- Lundbeck LLC$885
- Otsuka America Pharmaceutical, Inc.$883
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$865
- plus $3K from 20 others
What the payments were for
- Food & beverage$10,604100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 187 | $2,869 |
| Sunovion Pharmaceuticals Inc. | 112 | $1,460 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $980 |
| Lundbeck LLC | 61 | $885 |
| Otsuka America Pharmaceutical, Inc. | 48 | $883 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $865 |
| Alkermes, Inc. | 41 | $775 |
| Vanda Pharmaceuticals Inc. | 24 | $501 |
| Teva Pharmaceuticals USA, Inc. | 15 | $214 |
| Axsome Therapeutics, Inc. | 9 | $206 |
| Johnson & Johnson | 8 | $160 |
| Jazz Pharmaceuticals Inc. | 3 | $153 |
| Neurocrine Biosciences, Inc. | 7 | $119 |
| Idorsia Pharmaceuticals US Inc | 7 | $118 |
| Corium, LLC | 4 | $69 |
| Avanir Pharmaceuticals, Inc. | 3 | $51 |
| Neuronetics, Inc. | 1 | $48 |
| Almatica Pharma LLC | 2 | $42 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Harmony Biosciences LLC | 1 | $36 |
| Bausch Health US, LLC | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Eisai Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,607 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FetzimaLevomilnacipran Hcl | 11 | $11,250 |
| Lurasidone Hcl | 33 | $6,652 |
| Divalproex Sodium ErDivalproex Sodium | 21 | $4,588 |
| Bupropion XlBupropion Hcl | 91 | $3,011 |
| Duloxetine Hcl | 79 | $2,074 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 42 | $2,001 |
| Lamotrigine | 112 | $1,649 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $1,596 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 31 | $1,109 |
| Quetiapine Fumarate | 40 | $911 |
| Vilazodone Hcl | 14 | $831 |
| Aripiprazole | 35 | $742 |
| Clonazepam | 62 | $624 |
| Bupropion Hcl SrBupropion Hcl | 14 | $537 |
| Olanzapine | 18 | $494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieFetzima | $2,869 | $11,25011 claims |
| Almatica Pharma LLCSertraline Hcl | $42 | $42054 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $214 | $18318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Phoenix
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Eric ReimanPhoenix$157K
- Padma AkingPhoenix$44K
- Ahmed ElmaadawiPhoenix$32K
- Amnon KahanePhoenix$18K
- Aaron ClayPhoenix$14K
- Ivan EngelPhoenix$10K
- Holly HendinPhoenix$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.